BioNTech SE (NASDAQ: BNTX) is a biotechnology company specializing in mRNA-based therapies and immunotherapies. The firm rose to global prominence during the pandemic as the co-developer of the Pfizer-BioNTech COVID-19 vaccine. Shares now trade around $114, giving the company a market value of roughly $27.3 billion, after climbing 30% in the past year. Once a small German biotech focused on cancer treatments, BioNTech has evolved into a central figure in mRNA innovation with ambitions well beyond COVID.
Fueled by its breakthrough in vaccine technology and ongoing investment in oncology, infectious disease, and rare conditions, BioNTech has positioned itself as one of the leading players in the next wave of medical science. Its deep scientific expertise, strong partnerships, and significant cash reserves provide advantages that few competitors can match.
Once closely tied to its founders’ personal stakes, BioNTech is now attracting growing attention from major institutions. Founders and early backers still hold dominant positions, but large funds like Fidelity and T. Rowe Price have recently increased their exposure. This mix of concentrated insider ownership and rising institutional support reflects both long-term alignment and outside conviction.
Track the top shareholders of over 50,000 global stocks (It’s free) >>>
Who are BioNTech’s Top Shareholders?
See whether BioNTech’s top shareholders are buying or selling today >>>
BioNTech’s ownership is still dominated by its founding backers, with institutions beginning to scale up their positions. This mix of concentrated insider control and selective inflows makes the ownership picture unique compared to most large-cap biotechs.
- AT Impf GmbH: 101.9M shares (42.37%), ~$11.6B. Trimmed 636K shares (-0.62%).
- Medine GmbH: 40.1M shares (16.7%), ~$4.6B. Reduced 304K shares (-0.75%).
- Baillie Gifford: 8.0M shares (3.34%), ~$912.6M. Cut 121K shares (-1.48%).
- Fidelity (FMR LLC): 7.0M shares (2.9%), ~$792.2M. Added 1.02M shares (+17.2%).
- Pfizer Inc.: 3.7M shares (1.52%), ~$415.3M. Position unchanged.
- T. Rowe Price: 3.6M shares (1.50%), ~$408.5M. Boosted stake by 3.5M shares (+4,076.8%).
- CEO Ugur Sahin: 2.1M shares (0.85%), ~$232.8M. Reduced 725K shares (-26.1%).
The largest positions remain with AT Impf and Medine GmbH, together controlling close to 60% of the company, giving founders and early backers tight control.
One highlight from last quarter is Baker Bros Advisors’ aggressive move, boosting its BioNTech position by 719%. The fund now owns nearly 369K shares worth about $39 million, which looks like a strong conviction bet at a time when several other hedge funds have been reducing exposure.
Meanwhile, Baillie Gifford’s small reduction and CEO Ugur Sahin’s trimmed stake suggest some caution. In contrast, Fidelity’s 17% increase and T. Rowe Price’s dramatic repositioning point to fresh institutional confidence in BioNTech’s long-term pipeline.
BioNTech’s Recent Insider Activity
Insider activity at BioNTech over the past year has come mainly from directors and large beneficial owners. These were sales-related filings, with no significant insider buying reported.
- Helmut Jeggle (Director): Filed Form 144s in May and June 2025.
- Athos KG (Beneficial Owner >10%): Filed several Form 144s from November 2024 through June 2025.
- Ryan Richardson (Officer): Filed Form 144 in February 2025.
- Medine GmbH (Beneficial Owner >10%): Filed Form 144 in February 2025.
- Sierk Poetting (Officer): Filed Form 144 in February 2025.
The absence of insider buying suggests leadership is not signaling confidence at the current share price. Large holders like Athos KG remain active in selling, which keeps pressure on near-term sentiment. At the same time, insiders still hold meaningful stakes, so there’s still overall alignment with long-term shareholders.
See recent insider trade data for over 50,000 global stocks (It’s free) >>>
What the Ownership & Insider Trade Data Tell Us
BioNTech’s ownership is concentrated, with AT Impf and Medine GmbH holding nearly 60% of shares. This provides stability but limits outside influence. At the same time, Fidelity and T. Rowe Price have increased their stakes, showing that some institutions see potential in BioNTech’s pipeline.
Insider activity has mostly been sales-related filings from large holders such as Athos KG and Helmut Jeggle, with no meaningful insider buying.
For investors, the picture is mixed. Founders remain heavily invested, institutions are selectively adding, but insiders are not signaling conviction at current prices. BioNTech’s future will likely depend on whether its mRNA and oncology programs can deliver growth beyond COVID.
Wall Street Analysts Are Bullish on These 5 Undervalued Compounders With Market-Beating Potential
TIKR just released a new free report on 5 compounders that appear undervalued, have beaten the market in the past, and could continue to outperform on a 1-5 year timeline based on analysts’ estimates.
Inside, you’ll get a breakdown of 5 high-quality businesses with:
- Strong revenue growth and durable competitive advantages
- Attractive valuations based on forward earnings and expected earnings growth
- Long-term upside potential backed by analyst forecasts and TIKR’s valuation models
These are the kinds of stocks that can deliver massive long-term returns, especially if you catch them while they’re still trading at a discount.
Whether you’re a long-term investor or just looking for great businesses trading below fair value, this report will help you zero in on high-upside opportunities.
Click here to sign up for TIKR and get our full report on 5 undervalued compounders completely free.
